Animal models related to developmental disorders: theoretical and pharmacological analyses.
D015116:5,7-Dihydroxytryptamine / Q000494:pharmacology; D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D001289:Attention Deficit Disorder with Hyperactivity / Q000139:chemically induced / Q000188:drug therapy / Q000209:etiology*; D001921:Brain / Q000187:drug effects; D003866:Depressive Disorder / Q000188:drug therapy; D002658:Developmental Disabilities; D004195:Disease Models, Animal; D006193:Haemophilus influenzae; D000882:Haplorhini; D006801:Humans; D006892:Hydroxydopamines / Q000494:pharmacology; D007854:Lead / Q000009:adverse effects; D008583:Meningitis, Haemophilus / Q000150:complications; D051379:Mice; D018377:Neurotransmitter Agents / Q000502:physiology; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects; D012559:Schizophrenia / Q000188:drug therapy; D012970:Sodium Glutamate / Q000009:adverse effects
D006892:Hydroxydopamines; D018377:Neurotransmitter Agents; D011954:Receptors, Dopamine; D007854:Lead; D015116:5,7-Dihydroxytryptamine; D000661:Amphetamine; D012970:Sodium Glutamate